News


The T-TAS-01 is now available with defined measurement parameters to detect abnormal primary haemostatic function.

Hart Biologicals is pleased to announce the availability of The Fiix™ Test as a fully validated and compliant IVD product.

With the diversity and availability of POCT continuing to rise, a new generation of tests is breaking down the barriers between laboratories and patients.

Hart Biologicals has recently announced the addition of its sixth product, Arachidonic Acid MEA, to its MEA range of platelet aggregation testing reagents.

At Hart Biologicals, we research and manufacture kits for the detection of blood and platelet disorders including that of systematic lupus erythematosus commonly known as Lupus or SLE. 

Hart Biologicals has recently launched two new products in their MEA range to monitor and test the platelet response of patients. 

Self-experimentation in medical research has contributed to some of the biggest breakthroughs in medical history, as exampled by Marie Curie, Dr Jonas Silk, Dr Barry Marshall and others, whose incredible stories have paved the way to the create some of the medical science we use routinely today. 

Looking forward to 2020

As 2019 draws to a close much has changed since the turn of the millennium in the pathology laboratory. 

Hart Biologicals is proud to distribute the HALYARD CLOtest Rapid Urease Test in the UK and Ireland, which is used to detect Helicobacter pylori (H. pylori) in thestomach and duodenum. 

The recently introduced Total Thrombus-Formation Analysis System (T-TAS), is a microchip-based flow chamber system designed to evaluate thrombogenicity in whole blood.

As Hart Biologicals celebrates its 10th anniversary since moving into its current headquarters location at Rivergreen Business Centre on the outskirts of Hartlepool, much has changed since those early days in September 2009.  

Sales Manager, Paul Bates, reviews the benefits of both point of care testing and laboratory testing.